Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
Time magazine has named Czech virologist Tomáš Cihlář among its 100 Most Influential People of 2025, recognising his work on ...
A team from Houston Methodist Research Institute recently showed that a nanofluidic implant delivered an HIV drug that achieved more potency than other forms of drug administration (oral) and other ...
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial. In the study, none of ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Gilead said Thursday that ...
The human immunodeficiency virus (HIV) is a pathogen so wily and protean that researchers rarely talk about curing infected patients, focusing instead on treatment and prevention. But in an ...
EDP-323, an investigational inhibitor of Respiratory Syncytial Virus (RSV), is showing promising results in Phase 2a trials. While other RSV therapies and vaccines are approved for prevention, EDP-323 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback